Metagenomi Appoints Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer

Metageno­mi, a genet­ic med­i­cines com­pa­ny with a ver­sa­tile port­fo­lio of whol­ly owned, next-gen­er­a­tion gene edit­ing sys­tems, today announced the appoint­ment of Sarah Noon­berg, M.D., Ph.D. as Chief Med­ical Offi­cer. In this role, Dr. Noon­berg will over­see the clin­i­cal devel­op­ment of Metagenomi’s drug can­di­dates and devel­op­ment strat­e­gy of the Company’s expand­ing ther­a­peu­tic pipeline.

“Dr. Noon­berg joins Metageno­mi at a piv­otal moment in our growth as we trans­late Metagenomi’s ini­tial pre­clin­i­cal pro­grams into nov­el ther­a­peu­tics and expand our pipeline to address a broad­er range of dis­ease areas,” said Bri­an C. Thomas, Ph.D., CEO and founder of Metageno­mi. ​“Dr. Noonberg’s tenure at Medi­va­tion and Bio­Marin togeth­er with her expe­ri­ence as Chief Med­ical Offi­cer of oth­er genet­ic med­i­cines com­pa­nies makes her the ide­al can­di­date to expand Metagenomi’s ther­a­peu­tic pipeline, lever­ag­ing our vast tool­box of next-gen­er­a­tion gene edit­ing technologies.”

“I am thrilled to be join­ing Metageno­mi at such a key stage. The Company’s metage­nomics-pow­ered dis­cov­ery plat­form and diverse gene edit­ing tool­box enable poten­tial­ly cura­tive approach­es for a vari­ety of dis­eases that lack opti­mal treat­ment strate­gies. I am excit­ed to help advance our ini­tial in vivo proof-of-con­cept stud­ies into near-term clin­i­cal devel­op­ment and expand our pipeline,” said Dr. Noon­berg. ​“I have ded­i­cat­ed my career to devel­op­ing tru­ly inno­v­a­tive med­i­cines, and that mis­sion is shared by every­one at Metagenomi.”

Pri­or to join­ing Metageno­mi, Dr. Noon­berg was Chief Med­ical Offi­cer of Maze Ther­a­peu­tics, where she built and led non­clin­i­cal and clin­i­cal devel­op­ment efforts to trans­late insights from human genet­ics into nov­el ther­a­peu­tics. Ear­li­er, she was Chief Med­ical Offi­cer of Nohla Ther­a­peu­tics, lead­ing clin­i­cal devel­op­ment of a pro­gram for hema­to­log­ic malig­nan­cies. Oth­er exec­u­tive lead­er­ship roles include a tenure as Head of Glob­al Clin­i­cal Devel­op­ment at Bio­Marin, where she advanced a broad port­fo­lio of pro­grams involv­ing bio­log­ics, anti­sense oligonu­cleotides, and gene ther­a­pies for rare, genet­i­cal­ly defined dis­eases. Fur­ther­more, as Senior Vice Pres­i­dent at Medi­va­tion, Dr. Noon­berg led trans­la­tion­al and ear­ly devel­op­ment activ­i­ties, as well as late-stage devel­op­ment of enza­lu­tamide (XTANDI™) for advanced prostate cancer.

Dr. Noon­berg cur­rent­ly serves on the Board of Direc­tors at Pro­tag­o­nist Ther­a­peu­tics and Neoleukin Ther­a­peu­tics. She trained in inter­nal med­i­cine at Johns Hop­kins Hos­pi­tal, received an M.D. from the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co, a Ph.D. in bio­engi­neer­ing from the Uni­ver­si­ty of Cal­i­for­nia, Berke­ley, and a B.S. in engi­neer­ing sci­ence from Dart­mouth College.

About Metageno­mi

Metageno­mi is a gene edit­ing com­pa­ny com­mit­ted to devel­op­ing poten­tial­ly cura­tive ther­a­peu­tics by lever­ag­ing a pro­pri­etary tool­box of next-gen­er­a­tion gene edit­ing sys­tems to accu­rate­ly edit DNA where cur­rent tech­nolo­gies can­not. Our metage­nomics-pow­ered dis­cov­ery plat­form and ana­lyt­i­cal exper­tise reveal nov­el cel­lu­lar machin­ery sourced from oth­er­wise unknown organ­isms. We adapt and forge these nat­u­ral­ly evolved sys­tems into pow­er­ful gene edit­ing sys­tems that are ultra-small, extreme­ly effi­cient, high­ly spe­cif­ic and have a decreased risk of immune response. These sys­tems fuel our pipeline of nov­el med­i­cines. Our goal is to rev­o­lu­tion­ize gene edit­ing for the ben­e­fit of patients around the world. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.